SR-202 (PPAR Antagonist): Selective PPARγ Inhibition for Metabolic and Immunometabolic Research

Executive Summary: SR-202 (PPAR antagonist, B6929) is a selective inhibitor of peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor central to glucose metabolism and adipocyte differentiation (APExBIO). It directly blocks thiazolidinedione (TZD)-stimulated coactivator recruitment and transcriptional activity. SR-202 suppresses PPAR-dependent adipocyte differentiation in vitro and reduces adipocyte hypertrophy and insulin resistance in vivo in high-fat diet and ob/ob mouse models. The compound is a white solid (MW 358.65, C11H17ClO7P2) and is soluble ≥50 mg/mL in DMSO, ethanol, and water. No clinical trials have been performed to date (APExBIO Product Page).

Biological Rationale

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear receptors that regulate gene expression in glucose and lipid metabolism (Xue et al., 2025). PPARγ, in particular, controls adipocyte differentiation, fatty acid storage, and insulin sensitivity. Dysregulation of PPARγ signaling is implicated in obesity, type 2 diabetes, and inflammatory states. Pharmacological modulation of PPARγ (by agonists or antagonists) is a validated approach for dissecting metabolic and immunometabolic pathways. SR-202 is a small-molecule, selective PPARγ antagonist that enables targeted inhibition of PPAR-dependent gene programs and cellular phenotypes, facilitating both mechanistic and translational research (Decoding PPARγ Antagonism – this article updates mechanistic depth on SR-202's role in nuclear receptor inhibition and macrophage polarization).

Mechanism of Action of SR-202 (PPAR antagonist)

SR-202 inhibits the activity of PPARγ by blocking the recruitment of the steroid receptor coactivator-1 (SRC-1) in the presence of thiazolidinediones (TZDs), such as pioglitazone. This disrupts TZD-induced transcriptional activation of PPARγ target genes (APExBIO). In cell models, SR-202 selectively antagonizes PPAR family members—especially PPARγ—without significant cross-reactivity to unrelated nuclear receptors. SR-202 suppresses PPARγ-driven adipocyte differentiation, both under hormonal and TZD stimulation. In vivo, SR-202 treatment in high-fat diet mouse models reduces adipocyte hypertrophy, improves systemic insulin sensitivity, and attenuates TNF-α elevation (Strategic Dissection of PPARγ Antagonism – this article extends on SR-202’s in vivo effects and translational potential).

Evidence & Benchmarks

• SR-202 selectively antagonizes PPARγ and inhibits adipocyte differentiation in vitro at concentrations ≥1 μM (APExBIO, product page).
• SR-202 reduces high-fat diet-induced adipocyte hypertrophy and insulin resistance in C57BL/6 and ob/ob mice in vivo (APExBIO, product page).
• SR-202 suppresses TZD-induced recruitment of SRC-1 and PPARγ transcriptional activity in cell-based reporter assays (APExBIO, product page).
• PPARγ activation regulates macrophage polarization via the STAT-1/STAT-6 pathway, impacting inflammatory and metabolic disease progression (Xue et al., 2025).
• SR-202 protects against elevated plasma TNF-α in high-fat diet mouse models (APExBIO, product page).

Applications, Limits & Misconceptions

SR-202 (PPAR antagonist) is an advanced tool for:

• Dissecting PPAR signaling pathways in metabolic and immunometabolic research (SR-202: Advanced Insights – this article highlights workflow scenarios, whereas the present article provides validated performance benchmarks).
• Probing the role of PPARγ in adipocyte differentiation, insulin resistance, and inflammatory mediator production.
• Modeling metabolic and obesity-related diseases at the cellular and organismal level.
• Serving as a reference compound for nuclear receptor inhibition studies.

Common Pitfalls or Misconceptions

• SR-202 has not been tested in human clinical trials; all efficacy claims pertain to preclinical models.
• The compound is selective for PPARγ, but may have off-target effects at high concentrations; titration is required for specificity.
• SR-202 is not a therapeutic agent; it is strictly a research tool compound.
• Long-term storage of solutions is not recommended due to stability concerns; always prepare fresh aliquots.
• SR-202 does not modulate non-nuclear receptor signaling pathways directly.

Workflow Integration & Parameters

SR-202 (PPAR antagonist, B6929, from APExBIO) is supplied as a white solid. The molecular weight is 358.65 (C11H17ClO7P2). It is soluble at concentrations ≥50 mg/mL in DMSO, ethanol, and water. For in vitro use, a working concentration range of 1–10 μM is typical for cell-based reporter or differentiation assays. For in vivo studies, dosing should be titrated based on animal weight and route of administration. SR-202 should be stored desiccated at room temperature; solutions should be freshly prepared, as long-term storage reduces potency. The compound is suitable for studies involving PPARγ-driven pathways, including insulin resistance, adipogenesis, and systemic inflammation models.

Conclusion & Outlook

SR-202 is a rigorously characterized, selective PPARγ antagonist that enables mechanistic interrogation of the PPAR signaling pathway in preclinical models. Its defined selectivity and robust in vitro/in vivo benchmarks make it a preferred reference tool for metabolic, obesity, and type 2 diabetes research. As a research compound from APExBIO, SR-202 offers reproducible performance for dissecting nuclear receptor-mediated mechanisms, but is not intended for clinical use. Future studies may expand the application of SR-202 in new immunometabolic disease models and combinatorial pathway analyses.

For detailed protocols and compound specifications, visit the SR-202 (PPAR antagonist) product page.